Treatment for liver cancer: From sorafenib to natural products

S Man, C Luo, M Yan, G Zhao, L Ma, W Gao - European journal of …, 2021 - Elsevier
Liver cancer most commonly develops in patients with chronic liver disease, the etiology of
which includes viral hepatitis (B and C), alcohol, obesity, dietary carcinogens, and so forth …

Imidazoles as potential anticancer agents

I Ali, MN Lone, HY Aboul-Enein - MedChemComm, 2017 - pubs.rsc.org
Cancer is a black spot on the face of humanity in this era of science and technology.
Presently, several classes of anticancer drugs are available in the market, but issues such …

Comprehensive review in current developments of imidazole‐based medicinal chemistry

L Zhang, XM Peng, GLV Damu… - Medicinal research …, 2014 - Wiley Online Library
Imidazole ring is an important five‐membered aromatic heterocycle widely present in natural
products and synthetic molecules. The unique structural feature of imidazole ring with …

The design and discovery of topoisomerase I inhibitors as anticancer therapies

E Martín-Encinas, A Selas, F Palacios… - Expert Opinion on Drug …, 2022 - Taylor & Francis
Introduction Cancer has been identified as one of the leading causes of death worldwide.
The biological target of some anticancer agents is topoisomerase I, an enzyme involved in …

Strategies targeting DNA topoisomerase I in cancer chemotherapy: camptothecins, nanocarriers for camptothecins, organic non-camptothecin compounds and metal …

K Gokduman - Current drug targets, 2016 - ingentaconnect.com
Topoisomerase I (Topo I) is a nuclear enzyme engaged in adjustment of DNA topological
structure during cell cycle by cleaving and reannealing one of the two strands of the DNA …

Topoisomerase inhibitors as anticancer agents: a patent update

DB Khadka, WJ Cho - Expert opinion on therapeutic patents, 2013 - Taylor & Francis
Introduction: Topoisomerases (topos) are nuclear enzymes that resolve topological
problems associated with DNA during various genetic processes. The essential role of topos …

A patent review of topoisomerase I inhibitors (2016–present)

A Selas, E Martin-Encinas, M Fuertes… - Expert Opinion on …, 2021 - Taylor & Francis
Introduction Topoisomerases are important targets for therapeutic improvement in the
treatment of some diseases, including cancer. Inhibitors and poisons of topoisomerase I can …

Topoisomerase 1B poisons: Over a half‐century of drug leads, clinical candidates, and serendipitous discoveries

MA Cinelli - Medicinal Research Reviews, 2019 - Wiley Online Library
Topoisomerases are DNA processing enzymes that relieve supercoiling (torsional strain) in
DNA, are necessary for normal cellular division, and act by nicking (and then religating) …

Identification, synthesis, and biological evaluation of metabolites of the experimental cancer treatment drugs indotecan (LMP400) and indimitecan (LMP776) and …

MA Cinelli, PVN Reddy, PC Lv, JH Liang… - Journal of medicinal …, 2012 - ACS Publications
Hydroxylated analogues of the anticancer topoisomerase I (Top1) inhibitors indotecan
(LMP400) and indimitecan (LMP776) have been prepared because (1) a variety of potent …

3-Arylisoquinolines as novel topoisomerase I inhibitors

DB Khadka, WJ Cho - Bioorganic & medicinal chemistry, 2011 - Elsevier
Topoisomerase I (topo I) is an essential enzyme for vital cellular processes. Inhibition of topo
I activities is lethal and leads to cell death, thus establishing topo I as a promising target for …